Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.

A number of other brokerages also recently issued reports on ICPT. Jefferies Group LLC reissued a “buy” rating and set a $275.00 target price on shares of Intercept Pharmaceuticals in a research note on Sunday, July 30th. Cantor Fitzgerald reissued an “underweight” rating and set a $69.00 target price (up from $60.00) on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 target price for the company in a research note on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $205.04.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.84% during mid-day trading on Friday, reaching $118.75. The company had a trading volume of 262,089 shares. The firm’s 50 day moving average price is $114.38 and its 200-day moving average price is $117.58. The company’s market capitalization is $2.98 billion. Intercept Pharmaceuticals has a 12 month low of $96.63 and a 12 month high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same period in the prior year, the business posted ($3.14) EPS. Equities research analysts anticipate that Intercept Pharmaceuticals will post ($14.05) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/02/valuengine-upgrades-intercept-pharmaceuticals-inc-icpt-to-hold.html.

In related news, Director Daniel G. Welch sold 217 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the transaction, the director now directly owns 3,710 shares of the company’s stock, valued at approximately $470,279.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Mark Pruzanski sold 40,000 shares of the stock in a transaction on Monday, June 26th. The stock was sold at an average price of $130.80, for a total value of $5,232,000.00. Following the completion of the transaction, the chief executive officer now directly owns 611,718 shares in the company, valued at $80,012,714.40. The disclosure for this sale can be found here. Insiders have sold 46,763 shares of company stock worth $6,051,960 in the last 90 days. Insiders own 9.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. WFG Advisors LP raised its position in shares of Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the period. US Bancorp DE purchased a new position in shares of Intercept Pharmaceuticals during the first quarter valued at $130,000. IFP Advisors Inc raised its position in shares of Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Intercept Pharmaceuticals during the first quarter valued at $170,000. 82.19% of the stock is currently owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.